Ulcerative Colitis Therapeutics Market Poised to Double by 2033 with Growing Research and Drug Approvals

The ulcerative colitis therapeutics market is on track to witness strong growth, driven by rising prevalence of the disease and increasing drug approvals. With major pharmaceutical players investing heavily in R&D, the market is expected to expand significantly through 2033.

The global ulcerative colitis therapeutics market was valued at USD 9.57 Billion in 2024 and is projected to grow from USD 10.39 Billion in 2025 to reach USD 20.06 Billion by 2033, registering a CAGR of 8.57% during the forecast period (2025–2033). Growing disease incidence worldwide, particularly in developed economies, along with an active pipeline of new treatment options, is expected to accelerate this growth.

👉 Download Sample

Ulcerative colitis is one of the two most common types of inflammatory bowel disease (IBD), alongside Crohn's disease. It is a chronic inflammatory disorder of the colonic mucosa, with symptoms ranging from diarrhea, abdominal pain, and blood in the stool, to fatigue, weight loss, and anemia. Lifestyle, genetics, environmental factors, abnormal immune response, and microbiome imbalances are key contributors to disease risk.

Key Growth Drivers

• Rising prevalence of ulcerative colitis: Over 2.23 million new cases were reported globally in 2020, with the U.S. alone recording 910,000 cases in 2018.

• Increased research and drug approvals: Recent FDA approvals of filgotinib and upadacitinib highlight the growing therapeutic pipeline.

• Strategic initiatives: Key players are pursuing collaborations and acquisitions, such as Pfizer’s 2022 acquisition of Arena Pharmaceuticals, to strengthen their immunology portfolios.

Market Challenges

The market faces restraints due to frequent patent expirations and terminated clinical trials. For example, Takeda discontinued its Phase III trial of ontamalimab in 2021, slowing pipeline development.

Regional Insights

• North America dominates the market, supported by high disease prevalence, strong R&D activity, and regulatory approvals. For instance, the FDA approved Bristol Myers Squibb’s Zeposia (ozanimod) for UC treatment in 2021.

• Europe holds the second-largest share, with Germany leading in market size and the UK growing fastest.

• Asia-Pacific is expected to witness rapid growth due to rising awareness, changing lifestyles, and the introduction of biosimilars like Torrent Pharmaceuticals’ Adfra in India.

Market Segmentation

• By Drug Class: TNF-alpha inhibitors, 5-aminosalicylates, corticosteroids, others

• By Gender: Men (largest share, CAGR 8.76%), Women

• By Disease Type: Total colitis (largest share, CAGR 8.36%), Left-sided colitis, Proctitis

• By Region: North America, Europe, APAC, Latin America, Middle East & Africa

Key Players

• AbbVie

• Janssen Biotech

• Takeda Pharmaceutical Company

• Gilead/Galapagos

• Pfizer

• Bristol Myers Squibb

• EA Pharma Co. Ltd

• Shire

• Celltrion

• InDex Pharmaceuticals

• Amgen

• Reistone Biopharma

• Eli Lilly and Company

Recent Developments

• September 2023: FDA approved subcutaneous administration of Entyvio (Takeda Pharmaceuticals) for maintenance therapy.

• October 2023: FDA authorized Velsipity (etrasimod) for treating moderately to severely active ulcerative colitis in adults.

The ulcerative colitis therapeutics market is witnessing a period of accelerated innovation, with biologics, biosimilars, and small molecules shaping the treatment landscape. Growing investments and strategic collaborations are expected to drive the next phase of expansion.

About Us:

Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.

Contact Us:

Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website: https://straitsresearch.com/